Managing anemia in lymphoma and multiple myeloma.

Therapeutics and Clinical Risk Management
G Birgegård

Abstract

Anemia is common in cancer, and lymphoproliferative disease is no exception. Erythropoiesis-stimulating agents (ESA) have been used for renal anemia since 1986, and considerably later in cancer anemia. The first studies were published around 1993, but the use of ESA did not become common in cancer anemia until in the late 1990s. Cancer anemia is still under-treated. This review gives an overview of the use of ESA in hematologic malignancies. A background is given about this treatment in the cancer field generally. The pathophysiology of cancer anemia is described with special emphasis on the disturbances in iron metabolism. Functional iron deficiency has been shown to be both frequent and important as a hindrance for response to ESA treatment, and recent studies are reported in some detail, where the use of intravenous iron was shown to improve the response rate of ESA treatment.

Citations

Jul 18, 2009·International Journal of Hematology·Tommaso CaravitaPaolo de Fabritiis
Dec 20, 2017·Journal of Cancer Research and Clinical Oncology·Aasems JacobDavid Sharon
May 19, 2012·Paediatrics and International Child Health·N LewisN Wright

❮ Previous
Next ❯

Software Mentioned

VAS
Sysmex
LASA
Coulter

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
Nahla A Al-AgeelKhalid A Alsaran
Current Opinion in Nephrology and Hypertension
James E Novak, Lynda A Szczech
© 2022 Meta ULC. All rights reserved